Specifically, the exposure of BCR-ABL1-positive CD34 cells to BMS-911543 and DAS, eliminates TKI-insensitive leukemic stem cells, suggesting that the dual targeting strategy involving inhibition of both BCR-ABL1 and JAK2 may reduce the risk of developing TKI resistance in CML patients [76]. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.